Price (90d)
No price history yet — the daily price refresh runs once a day.
Signal Score (90d)
110Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $31.37M | $-231.96M | $-3.17 |
| 2024 | $43.27M | $-130.87M | $-2.32 |
| 2023 | $46.02M | $-70.80M | $-1.82 |
| 2022 | $41.40M | $-102.25M | $-2.74 |
| 2021 | $36.94M | $-58.42M | $-2.03 |
Social Signal Score
Earnings
Wed, Nov 4(in 3 months)
Consensus estimate $-0.89 per share
Typical surprise -10.4% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 5$-1.09 vs $-1.01miss
- Wed, May 6$-0.99 vs $-0.79miss
- Wed, Mar 4$-0.81 vs $-0.78miss
- Wed, Nov 5$-0.85 vs $-0.77miss
- Wed, Aug 6$-0.85 vs $-0.67miss
- Wed, May 7$-0.65 vs $-0.65beat
Estimates and results for EYPT via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Valuation
EYPThas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Mentions (1)
- Newsglobenewswire.com·23h ago·Positive
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) WATERTOWN, Mass., Aug. 14, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company's 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4).
View source ↗